Inhibition of Zymosan-Induced Inflammatory Factors Expression by ATRA Nanostructured Lipid Carriers

Figure 3

The effects of ATRA-NLCs on MMP-1, MMP-3, and MMP-13 and TIMP-1 and TIMP-2 TLR₂ expression in RCFs stimulated with zymosan. RCFs were incubated with or without ATRA-NLC for 24 h and then treated with zymosan. The immunoblot analysis showed that ATRA-NLCs inhibited the zymosan-mediated stimulation of MMP-1, MMP-3, and MMP-13 and TIMP-1 and TIMP-2 TLR₂.